Skip to content
Meta-analysis Open access

Changes in vascular structure and function in primary hyperparathyroidism: a systematic review and meta-analysis

Aug 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 147 references
Medicine

TL;DR

Findings support a model in which Primary hyperparathyroidism primarily affects vascular function through endothelial impairment, followed by mild structural remodeling, rather than advanced atherosclerotic plaque formation.

Abstract

Introduction Cardiovascular (CV) diseases, particularly ischemic heart disease and stroke, remain the leading cause of mortality worldwide and constitute a major global health challenge. Primary hyperparathyroidism (PHPT), a prevalent endocrine disorder, has recently emerged as a potential contributor to CV risk, although its impact on vascular structure and function has yet to be fully elucidated. Aim This systematic review and meta-analysis aimed to provide an in-depth characterization of vascular involvement by assessing markers of vascular remodeling and function in PHPT, including carotid intima-media thickness (IMT), carotid plaque prevalence, brachial artery flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD), as well as the effects of parathyroidectomy (PTX) on these parameters. Methods A comprehensive literature search was conducted across four databases (PubMed, Embase, Web of Science and Scopus) until March 2026. Original studies written in English enrolling patients with PHPT and assessing the pre-specified vascular markers using ultrasound evaluation were included. Thirty-two studies were eligible for the qualitative synthesis, of which thirty were included in the meta-analysis. Results Compared with controls, PHPT patients exhibited significantly increased carotid IMT and markedly reduced FMD, indicating early structural arterial changes and endothelial dysfunction. No significant differences were observed in carotid plaque prevalence or in NMD, the latter suggesting preserved endothelium-independent vascular function. PTX was associated with a modest short-term reduction in carotid IMT at 6 months, while improvements in endothelial function were inconsistent and did not reach statistical significance. Conclusion Overall, these findings support a model in which PHPT primarily affects vascular function through endothelial impairment, followed by mild structural remodeling, rather than advanced atherosclerotic plaque formation. These alterations may represent an early and potentially reversible stage of vascular disease. Although current guidelines do not include CV involvement as an indication for surgery, vascular markers may contribute to improved risk stratification and management decisions in PHPT. Further prospective studies employing standardized vascular assessment methodologies are needed to clarify the clinical significance of these findings.

Read PDF

Similar papers

Open access Oct 2026

Effects of colchicine on cardiac structure and function in patients with hypertension: a prespecified secondary analysis of the COlchicine HypERtENsion Trial (COHERENT)

Hypertension is a common and important risk factor for cardiovascular (CV) disease. The immune system and inflammatory response contribute to the pathology of hypertension. Colchicine has shown promise in delaying the progression of manifest atherosclerotic disease. However, the effects of colchicine on cardiac s...

A. Langhoff, N. Johansen, K. Bartholdy et al. · 0 citations
Review Open access Oct 2026

Non-atherosclerotic vasculopathies in stroke: a pathobiology-based framework

Non-atherosclerotic vasculopathies (NAV) are important causes of stroke, particularly in younger adults, but remain difficult to classify due to overlapping mechanisms and imaging features. This study aimed to propose a three-compartment framework that organises NAV according to the dominant biological proce...

A. Makharia, Divyani Garg, A. Srivastava et al. · 0 citations
Open access Oct 2026

The Interplay Between Klotho, Aldosterone, and Vascular Damage in Chronic Kidney Disease: Insights from a Cross-Sectional Study.

BACKGROUND Patients with chronic kidney disease (CKD) are at increased risk of vascular calcification and cardiovascular mortality. Reduced Klotho levels have been associated with vascular damage in CKD through both direct and indirect mechanisms. Klotho deficiency, a hallmark of CKD, has been suggested to contribute t...

L. Tartaglione, S. Rotondi, M. Pasquali et al. · 0 citations
Open access Oct 2026

Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death

Primary aldosteronism (PA) is a state of autonomous, renin-independent aldosterone production. It is linked with harmful metabolic and cardiovascular effects, however limited research has explored its impact on long term clinical outcomes. To evaluate the impact of subclinical primary aldosteronism in the...

A. Angélico-Gonçalves, A. R. Leite, T. Godinho et al. · 0 citations
Review Open access Sep 2026

Major cardiovascular, metabolic, and hypertension outcomes of coenzyme Q10 supplementation in elderly patients: a systematic review and meta-analysis

Introduction: The aging of the world's population poses unprecedented challenges to maintaining the health of the 9.1 billion people who will inhabit the planet by 2050. Dietary habits, which lead to the development of cardiovascular and metabolic diseases, significantly increase the risk of death. Objective: This was...

Aline Damasceno de Avance, I. Zotarelli, Orlando Thome et al. · 0 citations
Review Sep 2026

Lipid metabolism in moyamoya disease: Emerging evidence, vascular remodeling, and therapeutic implications

Evidence on lipid metabolic abnormalities in MMD is summarized, including clinical associations, lipid-related markers, multi-omics findings, potential mechanisms, and therapeutic implications of lipid-modulating approaches.

Xing-Lin Chen, Chu-Tong Guo, Mei-Qi Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.